Galapagos has discovered GLPG3312, a first generation compound against a novel and undisclosed inflammation target class, and it started Phase 1 trial.
In the Monday announcement, the company said that the Phase 1 trial is a double-blind, placebo-controlled, single-center study evaluating the efficacy, safety, tolerability, and PK/PD[1] of GLPG3312 in 76 adult healthy male volunteers.
GLPG3312 is an investigational drug with efficacy and safety yet to be established.
Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos”We are excited by the rapid progression of our Toledo program into the clinic. Thanks to its unique mechanism of action, the Toledo program has the potential to become a new paradigm in the treatment of inflammatory diseases.”
“Toledo” is a code name for a novel class discovered by Galapagos. The target family has a dual mode of action on inflammation by stimulating anti-inflammatory cytokines and inhibiting pro-inflammatory cytokines. The company have observed unprecedented activity in various inflammatory preclinical models with compounds targeting the class. Galapagos noted in the announcement that it is executing on a broad program to discover and develop multiple series of compounds acting on Toledo, aimed at activity across several inflammatory conditions.